UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Johnson RK
(2022)
Discovering metabolite quantitative trait loci in asthma using an isolated population.
in The Journal of allergy and clinical immunology
Johnson R
(2022)
Polygenic Scores for Plasticity: A New Tool for Studying Gene-Environment Interplay.
in Demography
Johnson R
(2021)
Estimation of regional polygenicity from GWAS provides insights into the genetic architecture of complex traits
in PLOS Computational Biology
Johnson J
(2022)
Added Sugars Intake Explained by Amino Acid Carbon Isotope Ratio Profiles in a Controlled Feeding Study of U.S. Adults
in Current Developments in Nutrition
Johnson EC
(2018)
Relationships between estimated autozygosity and complex traits in the UK Biobank.
in PLoS genetics
Johnson EC
(2021)
Polygenic contributions to alcohol use and alcohol use disorders across population-based and clinically ascertained samples.
in Psychological medicine
Johnsen PV
(2021)
A new method for exploring gene-gene and gene-environment interactions in GWAS with tree ensemble methods and SHAP values.
in BMC bioinformatics
John C
(2022)
Genetic Associations and Architecture of Asthma-COPD Overlap.
in Chest
Johansson Å
(2022)
Investigating the Effect of Estradiol Levels on the Risk of Breast, Endometrial, and Ovarian Cancer.
in Journal of the Endocrine Society
Johansson Å
(2019)
Genome-wide association analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema.
in Human molecular genetics
Johansson T
(2022)
Oral Contraceptives, Hormone Replacement Therapy, and Stroke Risk.
in Stroke
Jin X
(2022)
Network regression analysis in transcriptome-wide association studies.
in BMC genomics
Jin X
(2021)
Variance-component-based meta-analysis of gene-environment interactions for rare variants.
in G3 (Bethesda, Md.)
Jin C
(2022)
Association between dried fruit intake and pan-cancers incidence risk: A two-sample Mendelian randomization study.
in Frontiers in nutrition
Jiao Z
(2022)
A model-based approach to assess reproducibility for large-scale high-throughput MRI-based studies
in NeuroImage
Jiang X
(2020)
Fine-mapping and cell-specific enrichment at corneal resistance factor loci prioritize candidate causal regulatory variants.
in Communications biology
Jiang X
(2021)
The impact of age on genetic risk for common diseases.
in PLoS genetics
Jiang X
(2022)
Uncovering variable neoplasms between ATM protein-truncating and common missense variants using 394 694 UK Biobank exomes.
in Genes, chromosomes & cancer
Jiang X
(2022)
Urinary Sodium Excretion Enhances the Effect of Alcohol on Blood Pressure.
in Healthcare (Basel, Switzerland)
Jiang X
(2021)
The causal role of circulating vitamin D concentrations in human complex traits and diseases: a large-scale Mendelian randomization study.
in Scientific reports
Jiang W
(2021)
Relationship Between Fish Oil Use and Incidence of Primary Liver Cancer: Findings From a Population-Based Prospective Cohort Study.
in Frontiers in nutrition
Jiang T
(2023)
An empirical investigation into the impact of winner's curse on estimates from Mendelian randomization.
in International journal of epidemiology
Jiang R
(2023)
A functional connectome signature of blood pressure in >30 000 participants from the UK biobank.
in Cardiovascular research
Jiang R
(2022)
Associations between grip strength, brain structure, and mental health in > 40,000 participants from the UK Biobank.
in BMC medicine
Jiang L
(2022)
Lack of bidirectional association between age-related macular degeneration and Alzheimer's disease: A Mendelian randomization study.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Jiang L
(2021)
A generalized linear mixed model association tool for biobank-scale data.
in Nature genetics
Jiang L
(2021)
A Hierarchical Approach Using Marginal Summary Statistics for Multiple Intermediates in a Mendelian Randomization or Transcriptome Analysis.
in American journal of epidemiology
Jiang L
(2019)
A resource-efficient tool for mixed model association analysis of large-scale data.
in Nature genetics
Jiang H
(2021)
The effect of metabolic syndrome on head and neck cancer incidence risk: a population-based prospective cohort study
in Cancer & Metabolism
Jia Y
(2022)
Diet, Lifestyle Behaviours and Other Risk Factors Associated With Type 2 Diabetes Beyond Body Mass Index: A Mendelian Randomization Study.
in Canadian journal of diabetes
Jia T
(2020)
Thousands of missing variants in the UK Biobank are recoverable by genome realignment.
in Annals of human genetics
Jia P
(2022)
The genetic architecture of blood pressure variability: A genome-wide association study of 9370 participants from UK Biobank
in The Journal of Clinical Hypertension
Jia G
(2021)
Incorporating both genetic and tobacco smoking data to identify high-risk smokers for lung cancer screening
in Carcinogenesis
Jia G
(2022)
Discerning asthma endotypes through comorbidity mapping.
in Nature communications
Jia G
(2020)
Evaluating the Utility of Polygenic Risk Scores in Identifying High-Risk Individuals for Eight Common Cancers.
in JNCI cancer spectrum
Ji X
(2022)
HemoglobinA1c Is a Risk Factor for Changes of Bone Mineral Density: A Mendelian Randomization Study.
in Frontiers in endocrinology
Ji M
(2022)
Circulating C-reactive protein increases lung cancer risk: Results from a prospective cohort of UK Biobank.
in International journal of cancer
Jespersen J
(2022)
Genome-wide association study on cerebral white-matter hyperintensities in 36,577 individuals
in European Heart Journal
Jermy BS
(2022)
Using major depression polygenic risk scores to explore the depressive symptom continuum.
in Psychological medicine
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |